Filtered By:
Drug: Aspirin
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 3663 results found since Jan 2013.
The Effect of the ABCB1(MDR-1) C3435T Polymorphism in Turkish Patients with Aspirin Resistance in Acute Ischemic Stroke
This study aimed to investigate the rate of AR, the factors influencing AR in patients with acute ischemic stroke under regular aspirin use, and the relationship between AR and ABCB1 (MDR-1) C3435T (rs1045642) polymorphism. Throughout this multicenter prospective study, 174 patients with acute ischemic stroke who had been prescribed aspirin for at least one month due to the risk of vascular disease, along with 106 healthy volunteers, were included as part of the study group. The results of our study indicate that AR was detected in 21.3% of the patient group. According to the results of an analysis of the polymorphism of t...
Source: Translational Stroke Research - July 11, 2023 Category: Neurology Source Type: research
P014/130 Treatment of recurrent intracranial atherosclerotic disease-related stroke due to in-stent thrombosis with the CREDO(R) heal stent: A case report
ConclusionThis case highlights that re-stenting a recurrent ICAD-related stroke using the CREDO® heal stent is technically feasible, safe, and may improve clinical outcomes.Disclosure of InterestNothing to disclose.
Source: Journal of NeuroInterventional Surgery - August 21, 2023 Category: Neurosurgery Authors: Nguyen, A., Schulze-Zachau, V., Psychogios, M. Tags: 4.3 CASE PROPOSAL - Acute ischemic stroke Source Type: research
Rate Of Brain Hemorrhage In Stroke Patients Given TPA Isn't Meaningfully Higher
Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots. But when one of them suffers a stroke caused by a clot in their brain, some emergency teams might hesitate to give a powerful clot-busting medication called tPA -- for fear that the combination of drugs might cause dangerous brain bleeding. Now, a University of Michigan Stroke Program study suggests this fear may be unfounded, at least for most patients taking common clot-preventing therapies...
Source: Health News from Medical News Today - March 15, 2013 Category: Consumer Health News Tags: Stroke Source Type: news
Drug Combo Cuts Stroke Risk After TIA
A simple combination of two anti-clotting drugs, clopidogrel and aspirin, can cut the risk of a stroke in patients who have already experienced a mini-stroke or transient ischemic attack (TIA). This was the result of a phase 3 clinical trial conducted in China with the help of a US physician who says it could change the standard of care in the US. The investigators report their findings in the 26 June online issue of the New England Journal of Medicine, NEJM. The trial took place at several sites in China and was designed in partnership with S...
Source: Health News from Medical News Today - June 27, 2013 Category: Consumer Health News Tags: Stroke Source Type: news
Risk Of Stroke Effectively Reduced By Simple 2-Drug Combination
Results of a Phase III clinical trial showed that a simple drug regimen of two anti-clotting drugs - clopidogrel and aspirin- lowered the risk of stroke by almost one-third, compared to the standard therapy of aspirin alone, when given to patients who had minor or transient stroke symptoms to prevent subsequent attacks. Described this week in the New England Journal of Medicine (July 4, 2013 print issue), the clinical trial was conducted at multiple sites in China and designed in partnership with a physician at UC San Francisco...
Source: Health News from Medical News Today - June 28, 2013 Category: Consumer Health News Tags: Stroke Source Type: news
Clopidogrel Responsiveness in Stroke Patients on a Chronic Aspirin Regimen
This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day). Platelet function was measured using 3 different “point-of-care” platelet function analyzers: the Thrombelastograph hemostasis system, the Accumetrics VerifyNow system, and the Chronolog 570VS impedance aggregometer. Platelet function was assessed before administration of a 300-mg CPG loading dose and again at 26 hours and 64 hours after this loading dose along with a 75-mg daily maintenance dose. All 3 instruments detected marked ...
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2011 Category: Neurology Authors: Zohara Sternberg, Marilou Ching, Robert N. Sawyer, Trevor Chichelli, Fan Li, David Janicke, Vladan Radovic, Bijal Mehta, Osman Farooq, Frederick E. Munschauer Tags: Original Articles Source Type: research
Warfarin Versus Aspirin for Prevention of Cognitive Decline in Atrial Fibrillation: Randomized Controlled Trial (Birmingham Atrial Fibrillation Treatment of the Aged Study) Clinical Sciences
Conclusions—
We found no evidence that anticoagulation confers clinically important protection over aspirin against cognitive decline as measured by the Mini-Mental State Examination in atrial fibrillation in the first 33 months of treatment other than that provided by preventing clinical stroke.
Clinical Trial Registration—
URL: http://www.controlled-trials.com. Unique identifier: ISRCTN89345269.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Mavaddat, N., Roalfe, A., Fletcher, K., Lip, G. Y. H., Hobbs, F. D. R., Fitzmaurice, D., Mant, J. Tags: Arrhythmias, clinical electrophysiology, drugs, Primary and Secondary Stroke Prevention, Anticoagulants Clinical Sciences Source Type: research
Comparison of Aspirin Response Measured by Urinary 11-Dehydrothromboxane B2 and VerifyNow Aspirin Assay in Patients with Ischemic Stroke
Conclusions: Our research confirmed poor correlation and lack of agreement between the 2 tests. Only aspirin nonresponders who were diagnosed by dTXB2 measurement were related to having cardiovascular events and death. Further research is still needed to identify the best method of diagnosis of aspirin nonresponders.
Source: Journal of Stroke and Cerebrovascular Diseases - October 14, 2013 Category: Neurology Authors: Pornpatr A. Dharmasaroja, Suvaraporn Sae-Lim Tags: Original Articles Source Type: research
Dual antiplatelet therapy in recurrent stroke prevention: do the benefits outweigh the risks?
This study assessed seven randomised controlled trials, comprising 39 574 patients and comparing dual versus single antiplatelet therapies. Medications used included aspirin (50–325 mg daily), clopidogrel (75 mg daily), aspirin plus dipyridamole (50/400 mg daily) and ticlopidine (100 mg daily). Patients had a history of ischaemic stroke (three trials) or TIA (four...
Source: Evidence-Based Medicine - July 18, 2014 Category: Internal Medicine Authors: Farooq, M. U., Gorelick, P. B. Tags: Clinical trials (epidemiology), Stroke Therapeutics Source Type: research
Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin: A Randomized Controlled Trial Clinical Sciences
Conclusions—
Compared with aspirin, Terutroban did not beneficially affect progression of carotid atherosclerosis among well-treated patients with a history of ischemic stroke or transient ischemic attacks with an internal carotid stenosis <70%.
Clinical Trial Registration—
URL: http://www.controlled-trials.com. Unique identifier: ISRCTN66157730.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Bots, M. L., Ford, I., Lloyd, S. M., Laurent, S., Touboul, P. J., Hennerici, M. G., on behalf of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Isch Tags: Secondary prevention, Imaging, Antiplatelets Clinical Sciences Source Type: research
Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial Clinical Sciences
Conclusions—
Unexpected interactions between assigned antiplatelet therapy and each of ischemic heart disease and normal/prehypertensive status accounted for increased mortality among patients with recent lacunar stroke given dual antiplatelet therapy. Despite extensive exploratory analyses, the mechanisms underlying these interactions are uncertain.
Clinical Trial Registration—
URL: http://www.SPS3ClinicalTrials.gov. Unique identifier: NCT00059306.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Sharma, M., Pearce, L. A., Benavente, O. R., Anderson, D. C., Connolly, S. J., Palacio, S., Coffey, C. S., Hart, R. G. Tags: Cerebral Lacunes, Antiplatelets Clinical Sciences Source Type: research
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes
The objective of this study was to compare the effectiveness of different loading doses of aspirin in acute ischemic stroke presenting within 48 hours of symptom onset.
Source: Journal of Stroke and Cerebrovascular Diseases - July 3, 2016 Category: Neurology Authors: Tse-Hsuan Su, Yi-Ling Chan, Jiann-Der Lee, Meng Lee, Leng-Chieh Lin, Yu-Wen Wen, Tsong-Hai Lee Source Type: research
Letter by Moris et al Regarding Article, “Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)” Letter to the Editor
Source: Stroke - March 27, 2017 Category: Neurology Authors: Demetrios Moris, Chris Bakoyiannis, Efthymios Avgerinos Tags: Ischemic Stroke, Transient Ischemic Attack (TIA) Letters to the Editor Source Type: research
Response by Wang and Johnston to Letter Regarding Article, “Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)” Letter to the Editor
Source: Stroke - March 27, 2017 Category: Neurology Authors: Yongjun Wang, S. Claiborne Johnston Tags: Ischemic Stroke Letters to the Editor Source Type: research
